NBW Capital LLC lessened its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 8.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,646 shares of the biotechnology company’s stock after selling 2,261 shares during the period. NBW Capital LLC’s holdings in Blueprint Medicines were worth $2,876,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in BPMC. William Blair Investment Management LLC purchased a new position in shares of Blueprint Medicines in the 4th quarter valued at about $110,223,000. Natixis acquired a new stake in shares of Blueprint Medicines in the third quarter worth approximately $30,577,000. BlackRock Inc. increased its position in shares of Blueprint Medicines by 5.6% during the fourth quarter. BlackRock Inc. now owns 5,056,163 shares of the biotechnology company’s stock worth $567,048,000 after purchasing an additional 268,893 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Blueprint Medicines by 22.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,366,712 shares of the biotechnology company’s stock valued at $125,149,000 after purchasing an additional 251,884 shares during the last quarter. Finally, Alkeon Capital Management LLC raised its stake in Blueprint Medicines by 26.0% in the 3rd quarter. Alkeon Capital Management LLC now owns 897,500 shares of the biotechnology company’s stock valued at $83,198,000 after purchasing an additional 185,000 shares during the last quarter.
NASDAQ BPMC traded up $0.41 on Tuesday, reaching $98.37. The stock had a trading volume of 8,933 shares, compared to its average volume of 442,156. The firm has a market capitalization of $5.70 billion, a price-to-earnings ratio of 18.07 and a beta of 0.92. Blueprint Medicines Co. has a 12-month low of $43.29 and a 12-month high of $125.61. The stock has a fifty day moving average price of $101.02 and a two-hundred day moving average price of $96.56.
BPMC has been the subject of a number of recent research reports. Barclays increased their target price on shares of Blueprint Medicines from $90.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, February 18th. TheStreet downgraded shares of Blueprint Medicines from a “b-” rating to a “c+” rating in a report on Wednesday, January 27th. Piper Sandler boosted their target price on Blueprint Medicines from $77.00 to $81.00 and gave the stock a “neutral” rating in a report on Thursday, October 29th. BMO Capital Markets boosted their target price on Blueprint Medicines from $113.00 to $132.00 and gave the stock an “outperform” rating in a report on Monday, December 14th. Finally, JMP Securities boosted their target price on Blueprint Medicines from $118.00 to $152.00 and gave the stock an “outperform” rating in a report on Friday, December 18th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $112.20.
In other news, Director Charles A. Rowland, Jr. sold 10,909 shares of the company’s stock in a transaction on Thursday, December 17th. The stock was sold at an average price of $117.82, for a total transaction of $1,285,298.38. Following the sale, the director now owns 14,471 shares of the company’s stock, valued at $1,704,973.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark Alan Goldberg sold 5,455 shares of the company’s stock in a transaction on Thursday, December 24th. The stock was sold at an average price of $125.00, for a total value of $681,875.00. Following the sale, the director now directly owns 9,017 shares in the company, valued at approximately $1,127,125. The disclosure for this sale can be found here. Insiders have sold 22,576 shares of company stock worth $2,652,123 in the last ninety days. Corporate insiders own 3.81% of the company’s stock.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma.
Featured Article: Monthly Dividend Stocks Can Provide Solid Income
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMC).
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.